Tercica Touts Somatuline Dosing Advantage Over Sandostatin For Acromegaly
Executive Summary
Dosing advantages over Novartis' Sandostatin LAR is likely to be a key theme in Tercica's launch of its novel acromegaly treatment Somatuline Depot, approved Aug. 31